By Editor , 4 November 2026

Berlin – November 03, 2026 -- Net costs for outpatient drug care in Germany's statutory health insurance reached a record €62.6 billion, according to an analysis by the AOK's Scientific Institute (WIdO) on the 2027 pharmaceutical market. Dr. Carola Reimann, chair of the AOK Federal Association, warned that a planned location clause could erase the savings the current cost-containment package delivers.

By Editor , 4 November 2026
FX Shoulder Wins EU MDR Certification for Humelock Reversed

Addison, Texas – November 03, 2026 -- FX Shoulder Solutions has secured certification under the European Union Medical Device Regulation (EU MDR 2017/745) for its Humelock Reversed Shoulder System, the first step in a plan to harmonize its product portfolio across international markets.

The company says the certification supports continued availability of the device in EU markets. Humelock Reversed is the legacy device to the FX V135 Humelock.

By Editor , 4 November 2026
201 Tobacco Firms Urge von der Leyen to Rethink EU Nicotine Rules

Berlin – November 03, 2026 -- A coalition of 201 companies, associations and organizations from Europe's tobacco and nicotine value chain has appealed to European Commission President Ursula von der Leyen to change course on pending EU regulation. The German industry association BVTE backs the initiative, which is dated November 3, 2026.

By Editor , 4 November 2026
German Asset-Locked Company Plan Draws Succession Expert Warning

Bonn – November 03, 2026 -- Germany's planned "Gesellschaft mit gebundenem Vermögen" would lock company assets into the entity permanently and make that decision irreversible, according to a framework concept presented in March 2026. Succession adviser Thorsten Luber of Luber Consulting warns that the model could erode flexibility, innovation incentives and access to financing.

By Editor , 3 November 2026
ACER: Eustream's 50%+ Gas Tariff Rise Falls Short of EU Rules

Slovakia – November 03, 2026 -- The EU Agency for the Cooperation of Energy Regulators (ACER) has found that Eustream's proposed gas transmission tariffs, which would raise charges by more than 50% midway through the current tariff period, do not comply with the EU Network Code on Harmonised Transmission Tariff Structures (NC TAR).

By Editor , 3 November 2026
NextEra, Dominion Accept 114 of 117 Virginia Merger Conditions

JUNO BEACH – November 03, 2026 -- NextEra Energy (NYSE: NEE) and Dominion Energy (NYSE: D) have accepted 101 of 117 regulatory conditions exactly as proposed and another 13 with enhancements or modifications. The conditions came from Virginia State Corporation Commission Staff and the Office of the Attorney General Division of Consumer Counsel. The companies set out their position in rebuttal testimony filed with the Commission in support of their proposed combination.

By Editor , 3 November 2026
Bridge to Life wins Health Canada license, FDA Breakthrough tag

Duluth, Georgia – November 03, 2026 -- Bridge to Life Ltd. has secured a Health Canada Medical Device License for its VitaSmart HOPE System and an FDA Breakthrough Device Designation for investigational use in donor intestines, widening the commercial reach of its organ perfusion platform in North America.

By Editor , 3 November 2026

Berlin – November 03, 2026 -- RWE and LEAG secured nine of the eleven power plants awarded in the first tender under Germany's Electricity Supply Security Act (Strom-VKG), and no battery storage project won an award, according to Deutsche Umwelthilfe (DUH).

By Editor , 3 November 2026
Two US School Safety Bills Tie Panic Alarms to Digital Maps

St. Cloud, Minn. – November 03, 2026 -- Two bipartisan bills before Congress would require panic alarms in US schools and set standards for federally funded emergency response maps. GeoComm, a public safety mapping provider, says an alert is only useful if 9-1-1 staff and first responders can immediately see where help is needed.

By Editor , 3 November 2026

STOCKHOLM – November 03, 2026 -- The U.S. Patent and Trademark Office has granted Moberg Pharma a patent on an improved dosing regimen for MOB-015, its topical onychomycosis drug, with a projected expiry in December 2041. The U.S. is the first market to grant a patent on the new dosing.